Download Basal Cell Nevus Syndrome - Dr. Daniel Berg

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Basal Cell Nevus
Syndrome
Daniel Berg M.D., FRCPC
Director, Dermatologic Surgery
University of Washington
Thank Goodness….. Shade at Last!
Basal Cell Nevus Syndrome
• Autosomal Dominant
–50% risk of passing on
• In the skin:
–Numerous Basal Cell Carcinomas
• Beginning at young age
• Sensitivity to Radiation Treatment
–Palmar Pits
BASAL CELL CARCINOMA (BCC)
• Commonest Cancer U.S.
800,000/yr
– 99% in Caucasians
– 95% between age 40-79
– 85% on Head & Neck
– Risk of Metastasis: Very Very Low
– Main potential problem: Local Invasion
EPIDEMIOLOGY
LIFETIME RISK OF BCC AND SCC
MEN:
18.6%
WOMEN:
18%
(based on B.C. data - lifespan 75 yrs.)
BCNS Time of Onset BCC
• Before puberty:
• By age 22:
15%
50%
• By age 35:
90%
• None over age 30:
10%
Remember this?
P
M
•DNA molecules make up genes
•Genes are blueprints for Proteins
•Proteins are the building blocks of
body functions
•Some proteins control cell growth
D
•Everyone has two copies of each gene
•One each from Mum and Dad
Tumor Suppressors
Proteins that normally act
as brake on cell growth.
P
Patched
Inhibits
Induces
Smo
Downstream
Target Genes
Growth
Patched
P
Normal
Cell
P
Cell at Risk
BCC Cell
UVB
Ultraviolet Light
Spring Break - circa 1900
BASAL CELL CARCINOMA
• CLINICAL PRESENTATION
•
•
•
•
Nodular
Superficial
Morpheaform
Pigmented
Nodular
Superficial
Pigmented
Morpheaform
Infiltrative
NonMelanoma Skin Cancer
Choice of Treatment
Balance:
CURE RATE
FUNCTIONAL RESULT
COSMETIC RESULT
Choice of Treatment
• Special Features in BCNS Patients:
– Numerous BCCs expected
• Save more complicated surgery
• Early detection more important
– Size
– Consequences if recurrence
– Pathology
– Patient Concerns
Treatments
• Topical
– 5FU (Effudex)
• Superficial only
– Imiquimod (Aldara)
• Just approved by FDA 2004
• Surgery
– ED&C (scrape and burn)
– Excision
• Mohs
• Regular
Treatments
• Radiation
– Not in BCNS
• Other
– PDT
ED & C (“scrape & burn”)
CURE FOR SMALL PRIMARIES >90%
• ADVANTAGES
– Inexpensive
– Outpatient Office Procedure
– Quick
• DISADVANTAGES
– High Recurrence Rate for Difficult Tumors
• Location, recurrent, deep
ED&C
Initial Lesion (BCC)
Curettage (after biopsy)
ED&C
Desiccation
Repeat X 3
Final Defect
ED&C
Typical Scar
SURGICAL EXCISION
CURE FOR PRIMARY TUMORS > 90%
• ADVANTAGES
– Inexpensive
– Often office or outpatient procedure
• DISADVANTAGES
– More difficult with recurrent, indistinct tumors
– Margin control difficult in some locations
PDT
• Not approved for BCC in USA
• Combination of Drug + Light
Effect
– Drug can be given as cream, by mouth or iv.
– Currently two topicals approved in USA (AK)
• Levulan Kerastick
• Metvix
– Some studies in BCC exist
• Metvix - 70% Cure at 2 years (Arch Derm 2004)
PDT
PDT Pathway
PDT Selectivity
Topical Imiquimod (Aldara)
• Approved FDA 2004 for Superficial BCC
– 5 nights per week
– Total 6 week course
– Cure 70-85%
– Not tested in lesions <1cm from eyes, nose,
mouth, ears
– Largest diameter 2cm
• Side Effects
– Significant irritation at site common
Topical Imiquimod
• Possible role in nodular BCC
– Cure Rates 12 weeks:
• Once daily 5nights per week: 70%
• Twice daily 7 nights per week:
76%
• Once daily 3 nights/ week: 60%
– Cure Rates 6 weeks
• Similar
MOHS MICROGRAPHIC
SURGERY
• Definition:
– The multistage excision of (non-melanoma
skin) cancer using meticulous histologic
examination of horizontal sections of removed
tissue to guide the excision.
– Allows maximal preservation of normal tissue
with the highest published cure rates for
selected tumors.
MOHS MICROGRAPHIC
SURGERY
• Useful for difficult tumors with lower cure
rates with standard methods:
– Recurrent
– Large
– Difficult Anatomic Locations on Face
– Clinically indistinct (ie margins difficult to
ascertain)
– Aggressive Pathology (Sclerosing)
3 - 4mm margin
WHERE TO
CUT?
2. Excise Stage 1
1. “Debulk”
Mohs
Micrographic
Surgery
2. Excise Stage 1
Initial Defect
3. Prepare
1. “Debulk”
Tissue
Initial Defect
Prepare Tissue
(Patient Waits)
Taking residual Tumor - Stage II
Map Stage 1
Positive
Repairing Defect
Clear Margins
Hierarchy of Options
•2nd Intention
•Primary Closure
•Skin Graft
-FTSG
-STSG
•Local Flap
-Advancement
-Rotation
-Transposition
-Pedicle
•2-Stage Local Flap
•Combination Repair
•Other
-Free Flap
-Tissue Expansion